Clinical Trial: TGRX-678 Pharmacokinetic Mass Balance

U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06986772) titled 'TGRX-678 Pharmacokinetic Mass Balance' on May 15.

Brief Summary: This is a pharmacokinetic study for [14C]TGRX-678 on mass balance to evaluate distribution, metabolism and excretion of TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Chronic Myeloid Leukemia

Intervention: DRUG: [14C]TGRX-678

Healthy subjects will be given TGRX-678 240 mg orally on day 1.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shenzhen TargetRx, Inc.

Disclaimer: Curated by HT Syndication....